cyrilzakka/clinical-trials huggingface dataset:
Identification of the Optimal Functional Lymphatic Vessel for Lymphaticovenous Anastomosis

The aim of this study is to further explore the optimal screening factors for functional lymphatic vessels in lymphaticovenous anastomosis in patients with lymphedema.

By analyzing the size of lymphatic vessels (0.3-0.6mm), ICG imaging, contraction characteristics of lymphatic vessels and lymphatic flow in patients with lymphedema, the effect of functional lymphatic vessel selection on lymphatic drainage in patients with lymphedema was judged during operation, so as to provide a more scientific basis for the selection of functional lymphatic vessels in clinical surgery.

Eligibility Criteria:
Inclusion Criteria:

* lymphedema Paitent

Exclusion Criteria:

* myoedema Paitent；lipedema Paitent
Temperature Monitoring in Cardiac Surgery: Agreement Between Different Clinical Methods

Observational study to compare core temperatures obtained by 6 methods in patients undergoing cardiac surgery under cardiopulmonary bypass.

This study compares the core temperatures obtained by means of different probes placed in nasopharinx, pulmonary artery, arterial outlet, venous inlet, bladder and forehead in patients undergoing cardiac surgery under cardiopulmonary bypass.

Eligibility Criteria:
Inclusion Criteria:

* Only patients requiring a pulmonary artery catheter were included.

Exclusion Criteria:

* Sepsis or previous fever.
* Previous bladder catheter without termistor
* Deep hypothermic circulatory arrest.
Procalcitonin in Pleural Pleuritis

The purpose of this study is to determine pleural level of procalcitonin in differents situations of pleuritis.

Determine pleural level of procalcitonin in pleuritis. Two periods First period evaluation in vitro study/ Determine adequat technique included type of samples tubes for adequat analysis.

Second periods : Patient with pleuritis . Empyema or not

Eligibility Criteria:
Inclusion Criteria:

* Pleuritis
* Hospitalisation

Exclusion Criteria:
Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders

Neuromyelitis optica (NMO) is a demyelinating and degenerative disorder of the central nervous system affecting vision and brain and spinal cord function which leads to accumulating disability with a 5 year-mortality of approximately 30%. Survivors are typically left with severe morbidity secondary to blindness, quadriparesis and respiratory failure. No agent has been found to be highly effective in halting disease activity.Based on recent outcomes of Multipotent mesenchymal stromal cells in autoimmune diseases including multiple sclerosis, and based on the mechanisms of neuromyelitis optica, the investigators anticipate that mesenchymal stem cells transplantation may provide lasting disease stability for neuromyelitis optica patients.

Primary objective was to assess feasibility and safety; the investigators compared adverse events from up to 3months before treatment until up to 12 months after the infusion.

As a secondary objective, the investigators chose efficacy outcomes to assess the Expanded Disability Status (EDSS)、annual relapse rate (ARR) and time to next relapse after transplant.

Third objective anterior visual pathway and pyramidal tract as a model of wider disease. Masked endpoint analyses was used for electrophysiological and selected imaging outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Clinically definite neuromyelitis optica or neuromyelitis optica spectrum disorder
* Age \> 18 year
* EDSS \> 3
* Progression continued relapses or worsening MRI after at least a year of attempted therapy as evidenced by one or more of the following:

  * Increase of 1 EDSS point (if baseline EDSS\<5.0) or 0.5 EDSS points (if baseline EDSS \>5.5)
  * Moderate-severe relapses in past 18 months
  * Gadolinium enhancing lesions (double or triple dose Gd)
  * 1 new T2 lesion
* Evidence of recent inflammatory disease, as evidenced by any one of the following:

  * 1 moderate-severe relapses in past 18 months
  * 1 Gd-enhancing lesions (single, double or triple dose Gd)
  * 1 new T2 lesion

Exclusion Criteria:

* Received Immune inhibitors immunomodulator during the three months before the trial
* Significant cardiac, renal, or hepatic failure or any other disease that may affect the results of the study
* Allergies
* Pregnant or possibly pregnant
* Cognitive decline to understand or sign the informed consent
* Brain tumor, HIV (+) tumor marker (+), blood pressure (BP): 200 /110 mmHg
* Judged not suitable by doctors
Observational Study of the Use of 8% Capsaicin Patch in Children 0 to 18 Years Old

Patients aged less than 18-y with validated 8% capsaicin patch treatment in routine healthcare will be offered to participate the study. If they accept it as well as their parents, they will be included in the study .

Medical data will be recorded and at home, the child or his family will collect pain assessment data.

Tolerance will be monitored at home by phone call from investigational team every 24 hours until normalization. (Less than 24 hours for 75%, 100% to 72 hours on unpublished personal series.) Children will be assessed via scales at inclusion and 1-month, 3-month and 6-month.

Children and teenagers aged less than 18-y, with chronic localized neuropathic pain, may be treated by capsaicin 8% patch. If this indication is validated in pediatric chronic pain consultation, they will be offered to participate the study. If they accept it as well as their parents, they will be included in the study.

Treatment application will follow recommendations and be realized in out patient clinic with trained nurses.

Tolerance will be assessed by phone call every 24 Hours by investigational team until normalization. Expected duration is less than 24 Hours for 75% patients and 100 % at 72 Hours, from unpublished personal data.

Efficacy will be monitored with usual pain and neuropathic pain tools, adapted to age and cognitive capacities, one month after application.

Treatment may be done three times if needed with a three month interval between each capsaicin patch application.

Eligibility Criteria:
Inclusion Criteria:

* chronic localized neuropathic pain
* capsaicin 8% patch treatment indication validated in a pediatric chronic pain center
* agreement for participation by child and parents

Exclusion Criteria:

* already treated with capsaicin 8% patch in the same body area
* already treated in the same study in an other investigation center
* non willing to participate or parents not willing participation to the study
Lower Extremity Amputations in Persons With Diabetes Mellitus in the Netherlands

This is a retrospective, observational study based on an all-payer claims database (APCD) in the period 2011 to 2020) managed by the Vektis Health Care Information Center. In 2006, Vektis was established by Dutch health insurers aiming to combine and interpret reimbursement data and enable the main players in the Dutch healthcare market to base decisions and policy on reliable, essential, and timely information. Vektis receives data from all Dutch health care insurers. The APCD covers health care claims of 99.9% of the Dutch population. This study is part of the DUtch Diabetes Estimates (DUDE) initiative. We aim to perform different predefined analyses with the available data:

* What is the incident amputation rate in persons with and without DM in the Netherlands in the period 2011-2020?
* What defines persons with DM who need an amputation as compared to matched persons with DM but without an amputation in 2016, both in aspects of health care use and costs?
* What defines persons with DM who need an amputation as compared to matched persons without DM with an amputation?
* Does Social Economic Status (SES) play a role in amputation incidence and level, or on longer term outcome in persons with DM in the Netherlands?
* Does the presence of a formal multidisciplinary foot clinic / team in a hospital make a difference, especially when comparing previous and actual macrovascular complication rates?


Eligibility Criteria:
Inclusion Criteria:

* All persons aged ≥ 18 years, diagnosed with type 1 DM (T1DM) or type 2 DM (T2DM) identified in the Vektis data met the inclusion criteria

Exclusion Criteria:

* none
Diastolic RV EvAluation With Millar Catheter to Investigate the Effect of Glucagon-Like Peptide-1 (GLP-1) on Right Ventricular Function During Elective Coronary Angioplasty and Stenting

The heart requires nutrients and oxygen carried in the blood to generate energy for healthy pump function. Blood is supplied via heart vessels called coronary arteries. When the arteries narrow the investigators call this coronary artery disease. Narrowing and blockage of the coronary arteries can cause chest pain (angina), breathlessness (due to a reduction in pump function) and if prolonged even irreversible muscle damage known as a heart attack. The investigators can treat patients with coronary artery disease with drugs that reduce the workload on the heart or with balloons and hollow metal tubes (stents) to open the narrowed coronary arteries and improve the blood supply. These treatments can relieve angina, improve breathlessness and avert heart muscle damage during a heart attack. A potential new mechanistic effect is emerging by modulating the type of fuel used by the heart to generate energy more efficiently has been tested in the left ventricle. This study is designed to see if mechanistic effect provides the same protection in the right ventricle. It is hoped that this may further improve heart pump function and reduce the size of a heart attack in patients with coronary artery disease.


Eligibility Criteria:
Inclusion Criteria:

* Age over 18
* Able to give informed consent
* Elective percutaneous intervention for a single vessel right coronary artery stenosis \>75%
* Normal right ventricular function

Exclusion Criteria:

* Severe co-morbidity expected life (\<6months)
* Nicorandil or a GLP-1 receptor agonist or DPP-4 inhibitor use
* Women of child bearing age
* Myocardial infarction within the previous 3 months
* Previous coronary artery bypass graft to the RCA
* Significant known left to right shunt
* Permanent pacemaker
* Atrial fibrillation
Study on Gynecological Rare Cancers

This is a prospective, observational, multicenter study on gynecological rare tumors.

This is a prospective registry aimed to better understand prognosis, clinical and pathological features, management of this rare cancer conditions for improving standard of care.

Eligibility Criteria:
Inclusion Criteria:

* rare gynecological malignancies
* written informed consent
* patient fit for follow-up

Exclusion criteria

-written informed consent not provided
Efficacy of Gadoterate Meglumine in Diagnosis of Vascular Diseases Using MRA MRA

The purpose of this study is to compare magnetic resonance angiography (MRA) using gadoterate meglumine to clinically obtained MRA using gadobutrol. The specific aims are to show:

1. Carotid, chest, and abdomenal MRA with gadoterate meglumine has a comparable image quality and diagnostic confidence to MRA using gadobutrol.
2. Carotid, chest, and abdomenal MRA with gadoterate meglumine has a comparable accuracy for vascular lesion and stenosis detection compared to MRA using gadobutrol.

In this study, we will assess the image quality and accuracy of MRA studies acquired using these two contrast agents. In the cases where Digital Subtraction Angiography (DSA) or CT angiography images are available, the results of the study using both contrast agents will be compared to the DSA or CTA findings. All MRA images will be assessed independently by two readers. The readers will be blinded to the clinical symptoms, contrast agent and DSA/CTA results. A five-level system rating for image quality of each arterial segment will be used (1 = non-diagnostic images, 2 = poor image quality, significant blurring/artefacts, diagnosis suspected but not established, 3 = fair quality with established diagnosis, 4=good quality with definite diagnosis, minimal blurring/artefacts, 5 = sharply defined borders, excellent quality image information). Vascular lesions will also be graded on a 1-5 scale. Vessel segment stenoses will be graded using a five-point grading scale as follows: (1) normal; (2) mild (\<50% diameter stenosis); (3) moderate (50% to 74%), severe (75% to 99%); and (5) total occlusion.

Grades 1 and 2 will be considered insignificant, while grades 3 to 5 will be interpreted as significant for diagnostic accuracy testing.

Eligibility Criteria:
Inclusion Criteria:

* Male or female subjects 18-89 years of age
* Suspected or diagnosed vascular disease
* Standard of care carotid, chest, or
* Willingness to undergo 1 research MRA with up to double dose gadoterate meglumine
* Able to complete the MR safety questionnaire
* Able to comprehend and provide informed consent in English

Exclusion Criteria:

* • Allergy to gadolinium-containing contrast media

  * Chronic, severe kidney disease
  * eGFR \< 60mL/min/1.73m2
  * Acute kidney injury
  * Kidney or liver transplant within 8 weeks
  * Contraindication to MRI (implanted device, claustrophobia, dyspnea precluding the ability to follow breath-hold instructions)
  * Pregnant or breastfeeding women
  * Adults unable to consent
  * Individual who are not yet adults
  * Prisoners
Effects of Armeo Power Robot Therapy on Upper Limb Recovery in Hemiplegic Stroke Patients

This study investigates the effectiveness of combining Armeo Power robotic therapy with conventional rehabilitation techniques to improve upper limb motor function in patients with hemiplegia caused by supratentorial cerebral infarction (a type of stroke). The study aims to evaluate how robotic-assisted therapy can enhance recovery by measuring motor function improvements over three weeks of treatment. Participants will undergo standard physical and occupational therapy alongside Armeo Power training, with results compared to those receiving only standard rehabilitation. The findings aim to provide valuable insights into advanced therapeutic options for stroke rehabilitation.


Eligibility Criteria:
Inclusion Criteria

* Spasticity of the affected arm with a Modified Ashworth Scale score ≤ 2.
* Patients must have good cognition and awareness (MoCA score ≥ 26).
* Patients must have good vision and visual perception.
* Patients must have stable sitting posture and good sitting balance.
* Body weight and affected arm size must be compatible with the robotic arm device.
* Patients must agree to participate in the study and adhere to the training protocol.

Exclusion Criteria

* Spasticity with a Modified Ashworth Scale score ≥ 3.
* Severe sensory impairment in the affected limb.
* Patients with arthritis or joint stiffness.
* Hemiplegia caused by conditions other than stroke.
* Pre-existing motor disabilities in the affected limb before the stroke.
* Skin lesions on the limb requiring rehabilitation.
* Uncontrolled epilepsy.
Pre-operative MRI of Esophagus Cancer

The role of MRI in the management of esophageal cancer remains unclear and poorly studied. Recent technical advances suggest that MRI may become a powerful technique for the initial assessment of esophageal cancer, but also for the evaluation of response to neo-adjuvant treatment before surgery.

This imaging study will be performed prospectively and consecutively in 60 patients included over a 18-month period in patients wîth newly diagnosed esophageal cancer.

The aim of this study is to assess the accuracy of MRI to visualize esophageal tumors, to assess tumor burden and potential contact with adjacent structures as well as associated lymph nodes. If chemotherapy or radio-chemotherapy treatment is indicated before surgery, we will also evaluate whether MRI helps us to better evaluate the response to this treatment in comparison to PET-scan or echo. endoscopy which are the examinations currently performed to evaluate the effectiveness of these treatments.

The images of the MRI exams will be interpreted by 1 expert radiologist with no knowledge of the other imaging modalities and transmitted to the doctors in charge for possible consideration for the treatment.

Patients will then be followed for one year according to clinical management standards to study the data on treatment complications and cancer progression at one year.

The main risk is the administration of a gadolinium chelate-based MRI contrast product used routinely. There is also a risk that the results of the MRI may influence the treatment initially planned for example by canceling a surgical procedure.

The study will be proppsed consecutively to all patients with a histologically proven diagnosis of esophageal cancer.

An MRI examination including morphological sequences (without and with injection of a gadolinium chelate) functional and dynamic will be carried out in all the patients for initial staging in addition to other diagnostic procedure performed in clinical routine in this indication that are the endo-ultrasonography, CT and PET scanner.

In patients for whom neo-adjuvant treatment with chemotherapy or radio-chemotherapy will be decided and started, a second MRI will be performed 4 to 6 weeks after the end of the neo-adjuvant treatment.

The images of the MR exams will be interpreted by 1 expert radiologist blinded from data of other imaging modalities and transmitted to the doctors in charge of the patient for possible consideration for the treatment.

Patients will then be followed for one year according to regular recommandation to assess mortality / morbidity and PFS at 1 year.

Eligibility Criteria:
Inclusion Criteria:

* Any pathologically proven oesophagus cancer

Exclusion Criteria:

* MRI contraindication
* Pregnant women
* cervical esophagus cancer
Corneal Neurotization as a Treatment for Neurotrophic Keratopathy

The purpose of this study is to assess the efficacy of sural nerve transfer and cadaveric nerve graft to re-establish corneal sensation in patients with neurotrophic keratopathy.

Corneal anesthesia, which can lead to visually devastating outcomes from ulceration, perforation, and scarring, can be recalcitrant to both medical and surgical treatment\[1-3\]. Neurotization is a revolutionary technique reported to restore corneal sensation in neurotrophic keratopathy\[4-6\]. Prior techniques described include direct neurotization with contralateral supraorbital and supratrochlear nerves accessed via a bicoronal incision of the scalp over the forehead\[5\]; nerve grafting with contralateral supratrochlear nerves accessed via a medial upper eyelid incision\[6\]; and sural nerve grafting to contralateral supratrochlear nerves accessed via a transverse incision over the medial upper eyelid\[4\]. Despite the challenges associated with these techniques (needing to subcutaneously tunnel the nerve graft over the nasal bridge or requiring a large bicoronal incision), these techniques all demonstrated efficacy in direct neurotization to improve corneal sensation in these patients.

The investigators aim to assess the efficacy of this innovative surgical technique involving coaptation of the sural nerve or cadaveric nerve allograft to an intact sensory branch of the trigeminal nerve to restore corneal sensation. The investigators have previously described the anatomic feasibility of using the infraorbital nerve using a cadaveric model, of which the results were presented at the American Society of Ophthalmic Plastic and Reconstructive Society Fall meeting in 2017. Utilization of the infraorbital nerve provides advantages over existing techniques due to ease of access via a cosmetically favorable incision, large caliber with increased ability to create a perineural window, relatively short and direct tunnel with possibly more rapid neurotization, and absence of complex surrounding anatomical structures. Others have previously describe success using the contralateral and ipsilateral supraorbital nerve and supratrochlear nerve.

Eligibility Criteria:
Inclusion Criteria:

* Patients with neurotrophic cornea

Exclusion Criteria:

* Patients with history of penetrating keratoplasty
Comparison of the Absorption of Calcium Citrate and Calcium Carbonate in Patients With an RYGB, LSG, and OAGB

The precise impact of calcium absorption in relation to RYGB, SG, and OAGB remains under-researched in terms of statistical power and the diversity of BMS procedures considered. Therefore, this presents a critical area for future investigation to improve patient outcomes in BMS.

Calcium, predominantly absorbed in the duodenum and proximal jejunum, relies heavily on vitamin D and an acidic environment to facilitate absorption. With the increasing prevalence of bariatric metabolic surgery (BMS) procedures and their malabsorptive effects, the likelihood of fat-soluble vitamin malabsorption becomes heightened. This stems from bypassing the stomach, key absorption sites in the intestine, and the inefficient mixing of bile salts.

BMS is often associated with several bone metabolism disorders, including the acceleration of bone remodeling and turnover, bone loss, and decreased bone mineral density (BMD). Postoperative calcium supplementation can mitigate this bone loss over time. For instance, a study demonstrated the beneficial effect of calcium citrate following Roux-en-Y gastric bypass (RYGB). However, the study's statistical power was insufficient; thus, the BMS field still awaits further conclusive and robust research to establish definitive guidelines, which was highlighted in another study.

Moreover, substantial changes in gut hormones, such as peptide YY (PYY), glucagon-like peptide-1, and ghrelin, have been observed following RYGB, sleeve gastrectomy (SG), and One Anastomosis Gastric Bypass (OAGB). While these hormonal changes are typically associated with BMS's numerous positive metabolic benefits, they may also contribute to bone loss.

Consequently, the precise impact of calcium absorption in relation to RYGB, SG, and OAGB remains under-researched in terms of statistical power and the diversity of BMS procedures considered. Therefore, this presents a critical area for future investigation to improve patient outcomes in BMS.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18-75 years old
* After BMS surgery who had an RYGB, SG, or OAGB operation at least 12 months before the study.
* Patients will be selected at random from the hospital's electronic patient system.

Exclusion Criteria:

* Patients on antacids during the study
* Patients onH2 receptor antagonists during the study
* Patients on proton pump inhibitors during the study
* Patients with a previous oophorectomy,
* Liver disease,
* Renal disease,
* Hypercalcemia,
* Hyperthyroidism,
* Hypothyroidism who require levothyroxine supplementation (Levothyroxine forms complexes with calcium)
* Parathyroid disorders
* Use of diuretics,
* Use of calcitonin,
* Use of corticosteroids,
* Use of anabolic steroids,
* Use of anticonvulsants within three months of the study
* Heavy smokers (\>10 cigarettes/day)
* Abusing alcohol (\>70 ml/day)